Dr Reddy's Introduces Dedicated Division 'RGenX' to Enter Trade Generics Market

26 Jun 2023 , 10:10 AM

Dr Reddy’s Laboratories, a prominent pharmaceutical company, has made its foray into the trade generics sector in India by launching a specialized division known as ‘RGenX’.

Trade generics, unlike branded medicines, are directly sold through distributors and do not involve promotional campaigns.

Dr Reddy’s aims to expand the availability of its trade generics across various cities, towns, and even rural areas in India, ensuring widespread accessibility for patients. The company plans to collaborate closely with its channel partners to ensure the seamless availability of its products throughout the distribution network.

With the establishment of the trade generics division, Dr Reddy’s aims to offer patients a broader range of products while enhancing affordability. The company expressed its commitment to reaching over 1.5 billion patients by 2030 through this new business venture.

Dr Reddy’s entry into the trade generics market signifies its strategic efforts to diversify its product offerings and capture a larger market share. The move aligns with the company’s vision of addressing the healthcare needs of a vast population and improving patient outcomes.

By leveraging its expertise and strong distribution network, Dr Reddy’s aims to make a significant impact in the trade generics sector and contribute to the overall healthcare ecosystem in India. This strategic expansion marks a significant milestone for Dr Reddy’s Laboratories as it continues to play a vital role in the pharmaceutical industry, both nationally and internationally.

For feedback and suggestions, write to us at [e-mail]